HAEM5:High grade B-cell lymphoma with 11q aberrations - Revision history

Bailey.Glen at 17:16, 3 July 2025

2025-07-03T17:16:19Z

← Older revision		Revision as of 12:16, 3 July 2025
Line 36:		Line 36:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:35, 25 May 2025

2025-05-25T21:35:47Z

← Older revision		Revision as of 16:35, 25 May 2025
Line 87:		Line 87:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 182:		Line 182:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 251:		Line 251:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 305:		Line 305:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)

Bailey.Glen at 20:12, 25 May 2025

2025-05-25T20:12:07Z

← Older revision		Revision as of 15:12, 25 May 2025
Line 51:		Line 51:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Large B-cell lymphoma with 11q aberration
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Burkitt-like lymphoma with 11q aberration; MYC-negative Burkitt lymphoma (obsolete)
	\|}		\|}

Bailey.Glen at 17:37, 24 March 2025

2025-03-24T17:37:43Z

← Older revision		Revision as of 12:37, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}		{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 15:		Line 14:

	Daynna Wolff, PhD, Medical University of South Carolina		Daynna Wolff, PhD, Medical University of South Carolina

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: /* Gene Rearrangements */

2025-02-14T00:13:33Z

Gene Rearrangements

@@ Line 66: / Line 66: @@
 ==Gene Rearrangements==
-Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
+BLL-11q has no known gene fusions at this time.
 {| class="wikitable sortable"
 |-
@@ Line 74: / Line 74: @@
 !Established Clinical Significance Per Guidelines - Yes or No (Source)
 !Clinical Relevance Details/Other Notes
 |-
+|
@@ Line 126: / Line 85: @@
 |}
-BLL-11q has no known gene fusions at this time.
+<br />
 ==Individual Region Genomic Gain/Loss/LOH==

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-13T22:38:43Z

Gene Mutations (SNV/INDEL)

← Older revision		Revision as of 17:38, 13 February 2025
Line 308:		Line 308:

	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL)==
			Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
			{\| class="wikitable sortable"
			\|-
			!Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -'''
			'''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
			!'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T '''
			!'''Established Clinical Significance Per Guidelines - Yes or No (Source)'''
			!'''Clinical Relevance Details/Other Notes'''
			\|-
			\|<span class="blue-text">EXAMPLE:</span>''EGFR''

			<br />
			\|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Oncogene
			\|<span class="blue-text">EXAMPLE:</span> Common (lung cancer)
			\|<span class="blue-text">EXAMPLE:</span> T
			\|<span class="blue-text">EXAMPLE:</span> Yes (NCCN)
			\|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references).
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
			<br />
			\|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations
			\|<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene
			\|<span class="blue-text">EXAMPLE:</span> Common (breast cancer)
			\|<span class="blue-text">EXAMPLE:</span> P
			\|
			\|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer.
			\|-
			\|<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Activating mutations
			\|<span class="blue-text">EXAMPLE:</span> Oncogene
			\|<span class="blue-text">EXAMPLE:</span> Common (melanoma)
			\|<span class="blue-text">EXAMPLE:</span> T
			\|
			\|
			\|-
			\|
			\|
			\|
			\|
			\|
			\|
			\|
			\|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

	*Studies suggest an overall unique mutational profile, with little to no overlap with commonly mutated genes in DLCBL and BL, respectively. Notably, recurrent mutations in BL such as ID3, TCF3, and CCND3 were not present. <ref name=":6" /> <ref name=":13">{{Cite journal\|last=Wagener\|first=Rabea\|last2=Seufert\|first2=Julian\|last3=Raimondi\|first3=Francesco\|last4=Bens\|first4=Susanne\|last5=Kleinheinz\|first5=Kortine\|last6=Nagel\|first6=Inga\|last7=Altmüller\|first7=Janine\|last8=Thiele\|first8=Holger\|last9=Hübschmann\|first9=Daniel\|date=2019-02-28\|title=The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma\|url=https://ashpublications.org/blood/article/133/9/962/260647/The-mutational-landscape-of-Burkittlike-lymphoma\|journal=Blood\|language=en\|volume=133\|issue=9\|pages=962–966\|doi=10.1182/blood-2018-07-864025\|issn=0006-4971\|pmc=PMC6396176\|pmid=30567752}}</ref>		*Studies suggest an overall unique mutational profile, with little to no overlap with commonly mutated genes in DLCBL and BL, respectively. Notably, recurrent mutations in BL such as ID3, TCF3, and CCND3 were not present. <ref name=":6" /> <ref name=":13">{{Cite journal\|last=Wagener\|first=Rabea\|last2=Seufert\|first2=Julian\|last3=Raimondi\|first3=Francesco\|last4=Bens\|first4=Susanne\|last5=Kleinheinz\|first5=Kortine\|last6=Nagel\|first6=Inga\|last7=Altmüller\|first7=Janine\|last8=Thiele\|first8=Holger\|last9=Hübschmann\|first9=Daniel\|date=2019-02-28\|title=The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma\|url=https://ashpublications.org/blood/article/133/9/962/260647/The-mutational-landscape-of-Burkittlike-lymphoma\|journal=Blood\|language=en\|volume=133\|issue=9\|pages=962–966\|doi=10.1182/blood-2018-07-864025\|issn=0006-4971\|pmc=PMC6396176\|pmid=30567752}}</ref>

Bailey.Glen: /* Characteristic Chromosomal or Other Global Mutational Patterns */

2025-02-13T22:38:21Z

Characteristic Chromosomal or Other Global Mutational Patterns

@@ Line 237: / Line 237: @@
 ==Characteristic Chromosomal or Other Global Mutational Patterns==
 *Research up until this point has revealed no conservative breakpoints. <ref name=":3" />
@@ Line 272: / Line 306: @@
 |Noted to be recurrently concomitantly present with the characteristic proximal duplications and deletions that define BLL, 11q.<ref name=":5" />
 |}Notably, no 1q21 abnormalities were found in myc-negative, 11q positive cases. <ref name=":1">{{Cite journal|last=Horn|first=Heike|last2=Kalmbach|first2=Sabrina|last3=Wagener|first3=Rabea|last4=Staiger|first4=Annette M.|last5=Hüttl|first5=Katrin|last6=Mottok|first6=Anja|last7=Bens|first7=Susanne|last8=Traverse-Glehen|first8=Alexandra|last9=Fontaine|first9=Juliette|date=2021-03|title=A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas|url=https://journals.lww.com/10.1097/PAS.0000000000001613|journal=American Journal of Surgical Pathology|language=en|volume=45|issue=3|pages=356–364|doi=10.1097/PAS.0000000000001613|issn=0147-5185}}</ref><ref name=":6" />
 ==Gene Mutations (SNV/INDEL)==

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-13T22:37:55Z

Individual Region Genomic Gain/Loss/LOH

@@ Line 144: / Line 144: @@
 ==Individual Region Genomic Gain/Loss/LOH==
 The table below represents the smallest reported minimal lost region and smallest reported minimal gain region. Other larger MGR and MLR have been reported.<ref name=":2">{{Cite journal|last=Salaverria|first=Itziar|last2=Martin-Guerrero|first2=Idoia|last3=Wagener|first3=Rabea|last4=Kreuz|first4=Markus|last5=Kohler|first5=Christian W.|last6=Richter|first6=Julia|last7=Pienkowska-Grela|first7=Barbara|last8=Adam|first8=Patrick|last9=Burkhardt|first9=Birgit|date=2014-02-20|title=A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma|url=https://ashpublications.org/blood/article/123/8/1187/32820/A-recurrent-11q-aberration-pattern-characterizes-a|journal=Blood|language=en|volume=123|issue=8|pages=1187–1198|doi=10.1182/blood-2013-06-507996|issn=0006-4971|pmc=PMC3931189|pmid=24398325}}</ref> <ref>{{Cite journal|last=Ferreiro|first=J. F.|last2=Morscio|first2=J.|last3=Dierickx|first3=D.|last4=Marcelis|first4=L.|last5=Verhoef|first5=G.|last6=Vandenberghe|first6=P.|last7=Tousseyn|first7=T.|last8=Wlodarska|first8=I.|date=2015-07-01|title=Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern|url=http://www.haematologica.org/cgi/doi/10.3324/haematol.2015.124305|journal=Haematologica|language=en|volume=100|issue=7|pages=e275–e279|doi=10.3324/haematol.2015.124305|issn=0390-6078|pmc=PMC4486241|pmid=25795716}}</ref>
@@ Line 183: / Line 235: @@
 |Minimal duplication region contained PAFAH1B2, USP2, and CBL oncogenes.<ref name=":3" />
 |}
 ==Characteristic Chromosomal or Other Global Mutational Patterns==

Bailey.Glen: /* Gene Rearrangements */

2025-02-13T22:37:31Z

Gene Rearrangements

@@ Line 66: / Line 66: @@
 ==Gene Rearrangements==
 BLL-11q has no known gene fusions at this time.
@@ Line 83: / Line 142: @@
+|
 |}<br />
 ==Individual Region Genomic Gain/Loss/LOH==

Bailey.Glen: Removed old template contents

2025-02-13T02:32:27Z

Removed old template contents

Show changes